Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Begins Human Trials of a Potential COVID-19 Treatment

By Cory Renauer - Jun 11, 2020 at 10:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is using the same tech to fight the novel coronavirus as it used for its successful Ebola virus treatment.

Another new COVID-19 treatment candidate entered clinical-stage testing on Thursday. Regeneron (REGN 2.32%) has started a human trial of REGN-COV2, a pair of antibodies that glom onto SARS-CoV-2, the coronavirus that causes the illness, and stop it from entering host cells.

Earlier this month, Eli Lilly (LLY 1.90%) leaped ahead of Regeneron to become the first company to begin clinical testing of an antibody-based treatment for COVID-19, but REGN-COV2 is the first candidate that uses two antibodies working in concert to clear existing COVID-19 infections.

Doctor checking blood samples.

Image source: Getty Images.

Potential improvement 

In terms of the testing and approval process, both Regeneron's REGN-COV2 and Eli Lilly's LY-CoV555 are miles behind Gilead Sciences' (GILD 5.16%) remdesivir, a broad-spectrum antiviral that was given an emergency use authorization to treat COVID-19 in May, but they could be worth the wait. While remdesivir indiscriminately inhibits an enzyme that most viruses use to replicate themselves, the pair of proteins that make up REGN-COV2 were engineered to interfere specifically with the spikes that SARS-CoV-2 uses to enter host cells.

Since REGN-COV2 mimics antibodies found in patients who recovered from COVID-19, there's a good chance that it will be safe enough for use as a preventative measure. 

Winning track record

Regeneron used the same approach to develop REGN-COV2 as it used to develop REGN-EB3, the most successful Ebola virus treatment that has been found thus far. The company began studies with REGN-EB3 in 2018 and the FDA is still reviewing an application that was submitted for the treatment earlier this year.

The company will begin adaptive phase 1-3 studies that will look for safety signals from a small number of patients before ramping up to see if the treatment produces a measurable benefit. It is beginning with one trial for hospitalized COVID-19 patients and another for non-hospitalized patients.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$643.29 (2.32%) $14.58
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.21 (5.16%) $3.25
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$313.94 (1.90%) $5.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.